Login Register Cart 0
Current Cardiology Reviews

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Mitochondrial-Derived Peptides as Therapeutics and Biomarkers for Combating Vascular Aging and Associated Cardiovascular Diseases

Author(s): Rooban Sivakumar*orcid of author, Arul Senghor Kadalangudi Aravaanan, Vinodhini Vellore Mohanakrishnan and Janardhanan Kumar

Volume 22, Issue 1, 2026

Published on: 20 June, 2025

Article ID: e1573403X375709 Pages: 11

DOI: 10.2174/011573403X375709250616134726

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Vascular aging profoundly affects the onset of cardiovascular diseases in the elderly, mostly as a result of mitochondrial dysfunction. This review examines the protective roles of mitochondrial- derived peptides such as humanin, MOTS-c, and small humanin-like peptides in mitigating vascular aging. These peptides, encoded by mitochondrial DNA, are crucial for regulating apoptosis, inflammation, and oxidative stress, which have a major role in vascular health. MDPs have significant prospects as therapeutic and biomarker possibilities for the early diagnosis and intervention of vascular aging. MDPs influence the functions of endothelial and vascular smooth muscle cells by modulating critical signaling pathways, including AMPK, mTOR, and sirtuins. These pathways are essential for facilitating cellular metabolism, enhancing stress resilience, and prolonging longevity. Moreover, MDPs are essential in mitochondrial bioenergetics and dynamics, vital for mitigating endothelial dysfunction and enhancing vascular resilience. Furthermore, MDPs contribute to immunological modulation and the regulation of inflammatory responses, underscoring their potential therapeutic applications in the treatment of age-related vascular disorders. This review analyzes the various functions of MDPs in vascular health and their therapeutic importance, advocating for more studies to optimize their clinical benefits. By understanding the comprehensive roles and mechanisms of these multifunctional peptides, we can better appreciate their capacity to prevent and treat vascular aging and associated cardiovascular disorders. Future research should aim to further elucidate their therapeutic effects and optimize their clinical applications.

Keywords: Mitochondrial-derived peptides, vascular aging, oxidative stress, endothelial function, cardiovascular diseases, biomarkers.

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Zanelli S, Agnoletti D, Alastruey J, et al. Developing technologies to assess vascular ageing: A roadmap from VascAgeNet. Physiol Meas 2024; 45(12): 121001.
[http://dx.doi.org/10.1088/1361-6579/ad548e] [PMID: 38838703]
[2]
Maier JA, Andrés V, Castiglioni S, et al. Aging and vascular disease: A multidisciplinary overview. J Clin Med 2023; 12(17): 5512.
[http://dx.doi.org/10.3390/jcm12175512] [PMID: 37685580]
[3]
Ya J, Bayraktutan U. Vascular ageing: Mechanisms, risk factors, and treatment strategies. Int J Mol Sci 2023; 24(14): 11538.
[http://dx.doi.org/10.3390/ijms241411538] [PMID: 37511296]
[4]
Lacolley P. Cellular and molecular determinants of arterial aging. In: Early Vascular Aging (EVA) 133-43.
[http://dx.doi.org/10.1016/B978-0-443-15512-3.00041-6]
[5]
Basiuk A, Haieva K, Kalinichenko M, Mukhin L. Liubov Petelytska. Vascular aging: Pathophysiological mechanisms, clinical implications, and preventive strategies. Anti-Aging East Eur 2023; 2(2): 82-90.
[http://dx.doi.org/10.56543/aaeeu.2023.2.2.03]
[6]
Sutton NR, Malhotra R, St Hilaire C, et al. Molecular mechanisms of vascular health: Insights from vascular aging and calcification. Arterioscler Thromb Vasc Biol 2023; 43(1): 15-29.
[http://dx.doi.org/10.1161/ATVBAHA.122.317332] [PMID: 36412195]
[7]
Rodrigues T. Mitochondria and ageing.In: Cellular and Molecular Aspects of Ageing. 61-75.
[http://dx.doi.org/10.1007/978-3-031-55022-5_6]
[8]
Sarvari P, Sarvari P. Mitochondria: The master regulator of aging. INNOSC Theranostic Pharmacol Sci 2024; 7(2): 1726-6.
[http://dx.doi.org/10.36922/itps.1726]
[9]
Li Y, Jin X, Li D, et al. New insights into vascular aging: Emerging role of mitochondria function. Biomed Pharmacother 2022; 156: 113954-4.
[http://dx.doi.org/10.1016/j.biopha.2022.113954] [PMID: 36411638]
[10]
Ding W, Chen J, Zhao L, Wu S, Chen X, Chen H. Mitochondrial DNA leakage triggers inflammation in age-related cardiovascular diseases. Front Cell Dev Biol 2024; 12: 1287447.
[http://dx.doi.org/10.3389/fcell.2024.1287447] [PMID: 38425502]
[11]
Kirkman DL, Robinson AT, Rossman MJ, Seals DR, Edwards DG. Mitochondrial contributions to vascular endothelial dysfunction, arterial stiffness, and cardiovascular diseases. Am J Physiol Heart Circ Physiol 2021; 320(5): H2080-100.
[http://dx.doi.org/10.1152/ajpheart.00917.2020] [PMID: 33834868]
[12]
Kal S, Mahata S, Jati S, Mahata SK. Mitochondrial-derived peptides: Antidiabetic functions and evolutionary perspectives. Peptides 2024; 172: 171147-7.
[http://dx.doi.org/10.1016/j.peptides.2023.171147] [PMID: 38160808]
[13]
Li Y, Li Z, Ren Y, et al. Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities. J Adv Res 2024; 64: 99-115.
[http://dx.doi.org/10.1016/j.jare.2023.11.018] [PMID: 38008175]
[14]
Askin L, Tanriverdi O. Humanin and cardiovascular diseases. Cor Vasa 2023; 65(3): 533-7.
[http://dx.doi.org/10.33678/cor.2022.057]
[15]
Zhou Q, Yin S, Lei X, et al. The correlation between mitochondrial derived peptide (MDP) and metabolic states: A systematic review and meta-analysis. Diabetol Metab Syndr 2024; 16(1): 200.
[http://dx.doi.org/10.1186/s13098-024-01405-w] [PMID: 39160573]
[16]
Lin Z, Ding Q, Li X, et al. Targeting epigenetic mechanisms in vascular aging. Front Cardiovasc Med 2022; 8: 806988.
[http://dx.doi.org/10.3389/fcvm.2021.806988] [PMID: 35059451]
[17]
Ibarrola J, Kim SK, Lu Q, et al. Smooth muscle mineralocorticoid receptor as an epigenetic regulator of vascular ageing. Cardiovasc Res 2023; 118(17): 3386-400.
[http://dx.doi.org/10.1093/cvr/cvac007] [PMID: 35020830]
[18]
Somasundaram I, Jain SM, Blot-Chabaud M, et al. Mitochondrial dysfunction and its association with age-related disorders. Front Physiol 2024; 15: 1384966.
[http://dx.doi.org/10.3389/fphys.2024.1384966] [PMID: 39015222]
[19]
Tracy EP, Hughes W, Beare JE, Rowe G, Beyer A, LeBlanc AJ. Aging-induced impairment of vascular function: Mitochondrial redox contributions and physiological/clinical implications. Antioxid Redox Signal 2021; 35(12): 974-1015.
[http://dx.doi.org/10.1089/ars.2021.0031] [PMID: 34314229]
[20]
Ciccarelli G, Conte S, Cimmino G, Maiorano P, Morrione A, Giordano A. Mitochondrial dysfunction: The hidden player in the pathogenesis of atherosclerosis? Int J Mol Sci 2023; 24(2): 1086-6.
[http://dx.doi.org/10.3390/ijms24021086] [PMID: 36674602]
[21]
Nevzorova VA, Chertok VM, Brodskaya TA, Selyukova PA, Zakharchuk NV. Mitochondrial dysfunction and vascular aging in comorbid pathology. Pa Med J 2022; (1): 10-6.
[http://dx.doi.org/10.34215/1609-1175-2022-1-10-16]
[22]
Zhang Z, Huang Q, Zhao D, Lian F, Li X, Qi W. The impact of oxidative stress-induced mitochondrial dysfunction on diabetic microvascular complications. Front Endocrinol (Lausanne) 2023; 14: 1112363.
[http://dx.doi.org/10.3389/fendo.2023.1112363] [PMID: 36824356]
[23]
Liu Y, Huang Y, Xu C, et al. Mitochondrial dysfunction and therapeutic perspectives in cardiovascular diseases. Int J Mol Sci 2022; 23(24): 16053.
[http://dx.doi.org/10.3390/ijms232416053] [PMID: 36555691]
[24]
Pang B, Dong G, Pang T, et al. Emerging insights into the pathogenesis and therapeutic strategies for vascular endothelial injury-associated diseases: focus on mitochondrial dysfunction. Angiogenesis 2024; 27(4): 623-39.
[http://dx.doi.org/10.1007/s10456-024-09938-4] [PMID: 39060773]
[25]
Qu K, Yan F, Qin X, et al. Mitochondrial dysfunction in vascular endothelial cells and its role in atherosclerosis. Front Physiol 2022; 13: 1084604.
[http://dx.doi.org/10.3389/fphys.2022.1084604] [PMID: 36605901]
[26]
Yang J, Guo Q, Feng X, Liu Y, Zhou Y. Mitochondrial dysfunction in cardiovascular diseases: Potential targets for treatment. Front Cell Dev Biol 2022; 10: 841523.
[http://dx.doi.org/10.3389/fcell.2022.841523] [PMID: 35646910]
[27]
Xu M, Wang W, Cheng J, Qu H, Xu M, Wang L. Effects of mitochondrial dysfunction on cellular function: Role in atherosclerosis. Biomed Pharmacother 2024; 174: 116587-7.
[http://dx.doi.org/10.1016/j.biopha.2024.116587] [PMID: 38636397]
[28]
Li D, Yang S, Xing Y, et al. Novel insights and current evidence for mechanisms of atherosclerosis: Mitochondrial dynamics as a potential therapeutic target. Front Cell Dev Biol 2021; 9: 673839.
[http://dx.doi.org/10.3389/fcell.2021.673839] [PMID: 34307357]
[29]
Zhunina OA, Yabbarov NG, Grechko AV, et al. The role of mitochondrial dysfunction in vascular disease, tumorigenesis, and diabetes. Front Mol Biosci 2021; 8: 671908.
[http://dx.doi.org/10.3389/fmolb.2021.671908] [PMID: 34026846]
[30]
Mahoney SA, Venkatasubramanian R, Rossman M, et al. Fisetin supplementation improves age‐related vascular endothelial function by suppressing cellular senescence and mitochondrial oxidative stress. FASEB J 2022; 36(S1) fasebj.2022.36.S1.R1931.
[http://dx.doi.org/10.1096/fasebj.2022.36.S1.R1931 ]
[31]
Rossman MJ, Gioscia-Ryan RA, Clayton ZS, Murphy MP, Seals DR. Targeting mitochondrial fitness as a strategy for healthy vascular aging. Clin Sci (Lond) 2020; 134(12): 1491-519.
[http://dx.doi.org/10.1042/CS20190559] [PMID: 32584404]
[32]
Marzetti E, Csiszar A, Dutta D, Balagopal G, Calvani R, Leeuwenburgh C. Role of mitochondrial dysfunction and altered autophagy in cardiovascular aging and disease: From mechanisms to therapeutics. Am J Physiol Heart Circ Physiol 2013; 305(4): H459-76.
[http://dx.doi.org/10.1152/ajpheart.00936.2012] [PMID: 23748424]
[33]
Lin J, Gao P. 958 vascular mitophagy involved in vascular aging. J Hypertens 2012; 30 (Suppl. 1): e276-7.
[http://dx.doi.org/10.1097/01.hjh.0000420877.07675.77]
[34]
Zhang H, Muhetarijiang M, Chen RJ, et al. Mitochondrial dysfunction: A Roadmap for understanding and tackling cardiovascular aging. Aging Dis 2024.
[http://dx.doi.org/10.14336/AD.2024.0058] [PMID: 38739929]
[35]
Salazar G. NADPH oxidases and mitochondria in vascular senescence. Int J Mol Sci 2018; 19(5): 1327.
[http://dx.doi.org/10.3390/ijms19051327] [PMID: 29710840]
[36]
Uchikado Y, Ikeda Y, Ohishi M. Current understanding of the pivotal role of mitochondrial dynamics in cardiovascular diseases and senescence. Front Cardiovasc Med 2022; 9: 905072.
[http://dx.doi.org/10.3389/fcvm.2022.905072] [PMID: 35665261]
[37]
Poznyak AV, Kirichenko TV, Borisov EE, Shakhpazyan NK, Kartuesov AG, Orekhov AN. Mitochondrial implications in cardiovascular aging and diseases: The specific role of mitochondrial dynamics and shifts. Int J Mol Sci 2022; 23(6): 2951.
[http://dx.doi.org/10.3390/ijms23062951] [PMID: 35328371]
[38]
Madreiter-Sokolowski CT, Hiden U, Krstic J, et al. Targeting organ-specific mitochondrial dysfunction to improve biological aging. Pharmacol Ther 2024; 262: 108710-0.
[http://dx.doi.org/10.1016/j.pharmthera.2024.108710] [PMID: 39179117]
[39]
Forte M, Schirone L, Ameri P, et al. The role of mitochondrial dynamics in cardiovascular diseases. Br J Pharmacol 2021; 178(10): 2060-76.
[http://dx.doi.org/10.1111/bph.15068] [PMID: 32294237]
[40]
Ali MA, Gioscia-Ryan R, Yang D, Sutton NR, Tyrrell DJ. Cardiovascular aging: Spotlight on mitochondria. Am J Physiol Heart Circ Physiol 2024; 326(2): H317-33.
[http://dx.doi.org/10.1152/ajpheart.00632.2023] [PMID: 38038719]
[41]
Waldmann D, Lu Y, Cortada M, Bodmer D, Levano Huaman S. Exogenous humanin and MOTS-c function as protective agents against gentamicin-induced hair cell damage. Biochem Biophys Res Commun 2023; 678: 115-21.
[http://dx.doi.org/10.1016/j.bbrc.2023.08.033] [PMID: 37633181]
[42]
Yaşar E, Çakmak T, Bayramoğlu A. MOTS-c as a predictor of coronary lesions and complexity in patients with stable coronary artery disease. Eur Rev Med Pharmacol Sci 2022; 26(16): 5676.
[http://dx.doi.org/10.26355/eurrev_202208_29501]
[43]
Luo YH, Xie L, Li JY, Xie Y, Li MQ, Zhou L. Serum MOTS-C levels are decreased in obese children and associated with vascular endothelial function. Diabetes Metab Syndr Obes 2023; 16: 1013-20.
[http://dx.doi.org/10.2147/DMSO.S403934] [PMID: 37077579]
[44]
Wang M, Wang G, Pang X, et al. MOTS-c repairs myocardial damage by inhibiting the CCN1/ERK1/2/EGR1 pathway in diabetic rats. Front Nutr 2023; 9: 1060684.
[http://dx.doi.org/10.3389/fnut.2022.1060684] [PMID: 36687680]
[45]
Kim SJ, Miller B, Kumagai H, Yen K, Cohen P. MOTS-c: An equal opportunity insulin sensitizer. J Mol Med (Berl) 2019; 97(4): 487-90.
[http://dx.doi.org/10.1007/s00109-019-01758-0] [PMID: 30788534]
[46]
Gao Y, Wei X, Wei P, et al. MOTS-c functionally prevents metabolic disorders. Metabolites 2023; 13(1): 125-5.
[http://dx.doi.org/10.3390/metabo13010125] [PMID: 36677050]
[47]
Ahn CH, Choi EH, Kong BS, Cho YM. Effects of MOTS-c on the mitochondrial function of cells harboring 3243 A to G mutant mitochondrial DNA. Mol Biol Rep 2020; 47(5): 4029-35.
[http://dx.doi.org/10.1007/s11033-020-05429-z] [PMID: 32279209]
[48]
Alser M, Ramanjaneya M, Rizwana Anwardeen N, et al. The effect of chronic endurance exercise on serum levels of MOTS-c and humanin in professional athletes. Rev Cardiovasc Med 2022; 23(5): 181.
[http://dx.doi.org/10.31083/j.rcm2305181] [PMID: 39077591]
[49]
Lyu TJ, Zhang ZX, Chen J, Liu ZJ. Ginsenoside Rg1 ameliorates apoptosis, senescence and oxidative stress in ox LDL induced vascular endothelial cells via the AMPK/SIRT3/p53 signaling pathway. Exp Ther Med 2022; 24(3): 545.
[http://dx.doi.org/10.3892/etm.2022.11482] [PMID: 35978936]
[50]
Zheng XT, Wu ZH, Wei Y, et al. Induction of autophagy by salidroside through the AMPK-mTOR pathway protects vascular endothelial cells from oxidative stress-induced apoptosis. Mol Cell Biochem 2017; 425(1-2): 125-38.
[http://dx.doi.org/10.1007/s11010-016-2868-x] [PMID: 27848074]
[51]
Yang R, Fang W, Liang J, et al. Apelin/APJ axis improves angiotensin II-induced endothelial cell senescence through AMPK/SIRT1 signaling pathway. Arch Med Sci 2017; 14(4): 725-34.
[http://dx.doi.org/10.5114/aoms.2017.70340] [PMID: 30002688]
[52]
Shrosbery F, Czechtizky W, Donnelly L. Rapamycin reduces oxidative stress-induced senescence by increasing sirtuin-1 in small airway epithelial cells. European Respiratory J 2023; 62(67): PA566.
[http://dx.doi.org/10.1183/13993003.congress-2023.PA566]
[53]
Guo H, Ding H, Yan Y, et al. Intermittent hypoxia-induced autophagy via AMPK/mTOR signaling pathway attenuates endothelial apoptosis and dysfunction in vitro. Sleep Breath 2021; 25(4): 1859-65.
[http://dx.doi.org/10.1007/s11325-021-02297-0] [PMID: 33483906]
[54]
Arunachalam G, Samuel SM, Marei I, Ding H, Triggle CR. Metformin modulates hyperglycaemia‐induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 2014; 171(2): 523-35.
[http://dx.doi.org/10.1111/bph.12496] [PMID: 24372553]
[55]
Pulipaka S, Chempon H, Singuru G, et al. Mitochondria-targeted esculetin and metformin delay endothelial senescence by promoting fatty acid β-oxidation: Relevance in age-associated atherosclerosis. Mech Ageing Dev 2024; 219: 111931-1.
[http://dx.doi.org/10.1016/j.mad.2024.111931] [PMID: 38554949]
[56]
Mendelsohn AR, Larrick JW. Mitochondrial-derived peptides exacerbate senescence. Rejuvenation Res 2018; 21(4): 369-73.
[http://dx.doi.org/10.1089/rej.2018.2114] [PMID: 30058454]
[57]
Han Q, Yu Y, Liu X, et al. The role of endothelial cell mitophagy in age-related cardiovascular diseases. Aging Dis 2024.
[http://dx.doi.org/10.14336/AD.2024.0788] [PMID: 39122456]
[58]
Hansen CC, Gudiksen A, Van der Stede T, et al. Mitochondrial peptides derived from exercising skeletal muscle increase oxidative stress in microvascular endothelial cells. Physiology (Bethesda) 2024; 39(S1): 1417.
[http://dx.doi.org/10.1152/physiol.2024.39.S1.1417]
[59]
Zhang X, Xu X, Lu L, et al. A new Mfn-2 related synthetic peptide promotes vascular smooth muscle cell apoptosis via regulating the mitochondrial apoptotic pathway by inhibiting Akt signaling. J Transl Med 2021; 19(1): 395.
[http://dx.doi.org/10.1186/s12967-021-03064-1] [PMID: 34538249]
[60]
Dabravolski SA, Nikiforov NG, Starodubova AV, Popkova TV, Orekhov AN. The role of mitochondria-derived peptides in cardiovascular diseases and their potential as therapeutic targets. Int J Mol Sci 2021; 22(16): 8770.
[http://dx.doi.org/10.3390/ijms22168770] [PMID: 34445477]
[61]
Sadria M, Layton AT. Interactions among mTORC, AMPK, and SIRT: A computational model for cell energy balance and metabolism. Cell Commun Signal 2021; 19(1): 57.
[http://dx.doi.org/10.1101/2020.10.07.330308]
[62]
Cobb LJ, Lee C, Xiao J, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY) 2016; 8(4): 796-809.
[http://dx.doi.org/10.18632/aging.100943] [PMID: 27070352]
[63]
De Gaetano A, Solodka K, Zanini G, et al. Molecular mechanisms of mtDNA-mediated inflammation. Cells 2021; 10(11): 2898.
[http://dx.doi.org/10.3390/cells10112898] [PMID: 34831121]
[64]
Bencivenga L, Strumia M, Rolland Y, et al. Biomarkers of mitochondrial dysfunction and inflammaging in older adults and blood pressure variability. Geroscience 2023; 45(2): 797-809.
[http://dx.doi.org/10.1007/s11357-022-00697-y] [PMID: 36454336]
[65]
Neves J, Sousa-Victor P. Regulation of inflammation as an anti‐aging intervention. FEBS J 2020; 287(1): 43-52.
[http://dx.doi.org/10.1111/febs.15061] [PMID: 31529582]
[66]
Trott DW, Fadel PJ. Inflammation as a mediator of arterial ageing. Exp Physiol 2019; 104(10): 1455-71.
[http://dx.doi.org/10.1113/EP087499] [PMID: 31325339]
[67]
Li W, Zhang D, Yuan W, Wang C, Huang Q, Luo J. Humanin ameliorates free fatty acid-induced endothelial inflammation by suppressing the NLRP3 inflammasome. ACS Omega 2020; 5(35): 22039-45.
[http://dx.doi.org/10.1021/acsomega.0c01778] [PMID: 32923762]
[68]
Wu J, Xiao D, Yu K, Shalamu K, He B, Zhang M. The protective effect of the mitochondrial-derived peptide MOTS-c on LPS-induced septic cardiomyopathy. Acta Biochim Biophys Sin (Shanghai) 2023; 55(2): 285-94.
[http://dx.doi.org/10.3724/abbs.2023006] [PMID: 36786072]
[69]
Conte M, Martucci M, Chiariello A, Franceschi C, Salvioli S. Mitochondria, immunosenescence and inflammaging: A role for mitokines? Semin Immunopathol 2020; 42(5): 607-17.
[http://dx.doi.org/10.1007/s00281-020-00813-0] [PMID: 32757036]
[70]
Kim SJ, Miller B, Kumagai H, Silverstein CR. Mitochondrial-derived peptides in aging and age-related diseases. Geroscience 2020; 43(3): 1113-21.
[http://dx.doi.org/10.1007/s11357-020-00262-5]
[71]
Ungvari Z, Sonntag WE, Csiszar A. Mitochondria and aging in the vascular system. J Mol Med (Berl) 2010; 88(10): 1021-7.
[http://dx.doi.org/10.1007/s00109-010-0667-5] [PMID: 20714704]
[72]
Miller B, Kim SJ, Kumagai H, Yen K, Cohen P. Mitochondria-derived peptides in aging and healthspan. J Clin Invest 2022; 132(9)
[http://dx.doi.org/10.1172/JCI158449] [PMID: 35499074]
[73]
Acin-Perez R, Benincá C, Shabane B, Shirihai OS, Stiles L. Utilization of human samples for assessment of mitochondrial bioenergetics: Gold standards, limitations, and future perspectives. Life 2021; 11(9): 949.
[http://dx.doi.org/10.3390/life11090949] [PMID: 34575097]
[74]
Gropman AL, Uittenbogaard MN, Chiaramello AE. Challenges and opportunities to bridge translational to clinical research for personalized mitochondrial medicine. Neurotherapeutics 2024; 21: e00311.
[http://dx.doi.org/10.1016/j.neurot.2023.e00311]
[75]
Wei M, Gan L, Liu Z, et al. Mitochondrial-derived peptide MOTS-c attenuates vascular calcification and secondary myocardial remodeling via adenosine monophosphate-activated protein kinase signaling pathway. Cardiorenal Med 2020; 10(1): 42-50.
[http://dx.doi.org/10.1159/000503224] [PMID: 31694019]
[76]
Bachar AR, Scheffer L, Schroeder AS, et al. Humanin is expressed in human vascular walls and has a cytoprotective effect against oxidized LDL-induced oxidative stress. Cardiovasc Res 2010; 88(2): 360-6.
[http://dx.doi.org/10.1093/cvr/cvq191] [PMID: 20562421]
[77]
Zacharias DG, Kim SG, Massat AE, et al. Humanin, a cytoprotective peptide, is expressed in carotid atherosclerotic [corrected] plaques in humans. PLoS One 2012; 7(2): e31065-5.
[http://dx.doi.org/10.1371/journal.pone.0031065] [PMID: 22328926]
[78]
Szeto HH. Stealth peptides target cellular powerhouses to fight rare and common age-related diseases. Protein Pept Lett 2019; 25(12): 1108-23.
[http://dx.doi.org/10.2174/0929866525666181101105209] [PMID: 30381054]
[79]
Zimmermann A, Madreiter-Sokolowski C, Stryeck S, Abdellatif M. Targeting the mitochondria-proteostasis axis to delay aging. Front Cell Dev Biol 2021; 9: 656201.
[http://dx.doi.org/10.3389/fcell.2021.656201] [PMID: 33777963]
[80]
Murray KO, Ludwig KR, Darvish S, Coppock ME, Seals DR, Rossman MJ. Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress. Am J Physiol Heart Circ Physiol 2023; 325(1): H187-94.
[http://dx.doi.org/10.1152/ajpheart.00270.2023] [PMID: 37326998]
[81]
Gioscia-Ryan RA, Clayton ZS, Zigler MC, et al. Lifelong voluntary aerobic exercise prevents age‐ and Western diet‐ induced vascular dysfunction, mitochondrial oxidative stress and inflammation in mice. J Physiol 2021; 599(3): 911-25.
[http://dx.doi.org/10.1113/JP280607] [PMID: 33103241]
[82]
Dikalova AE, Pandey A, Xiao L, et al. Mitochondrial Deacetylase Sirt3 reduces vascular dysfunction and hypertension while Sirt3 depletion in essential hypertension is linked to vascular inflammation and oxidative stress. Circ Res 2020; 126(4): 439-52.
[http://dx.doi.org/10.1161/CIRCRESAHA.119.315767] [PMID: 31852393]
[83]
Kim SJ, Mehta HH, Wan J, et al. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY) 2018; 10(6): 1239-56.
[http://dx.doi.org/10.18632/aging.101463] [PMID: 29886458]
[84]
Ramanjaneya M, Bettahi I, Jerobin J, et al. Mitochondrial-Derived peptides are down regulated in diabetes subjects. Front Endocrinol (Lausanne) 2019; 10: 331.
[http://dx.doi.org/10.3389/fendo.2019.00331] [PMID: 31214116]
[85]
Gidlund EK, von Walden F, Venojärvi M, et al. Humanin skeletal muscle protein levels increase after resistance training in men with impaired glucose metabolism. Physiol Rep 2016; 4(23): e13063-3.
[http://dx.doi.org/10.14814/phy2.13063] [PMID: 27923980]
[86]
Bolignano D, Greco M, Presta P, et al. Unbalanced circulating Humanin levels and cardiovascular risk in chronic hemodialysis patients: A pilot, prospective study. J Nephrol 2024; 37(7): 1863-70.
[http://dx.doi.org/10.1007/s40620-024-02032-4] [PMID: 39102184]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 32
Html icon 3
Find your institution